Randomized, Double-blind, Placebo-controlled Trial of Nimodipine in Acute Ischemic Hemispheric Stroke


Phase N/A Results


There were no differences in functional outcome between the two groups. During the first month and at 3 months, there was a higher case-fatality rate in the nimodipine group than the placebo group (p=0.004 and p=0.030, respectively), but at 12 months this difference had lost statistical significance.